Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 571 AL 585

Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases

Yuan J, Amin P, Ofengeim D.

Nat Rev Neurosci. 2019 Jan;20(1):19-33. doi: 10.1038/s41583-018-0093-1.

Beta(1)-adrenergic receptor antibodies in children with dilated cardiomyopathy

Camino M, Morales MD.

Front Biosci (Elite Ed). 2019 Jan 1;11(1):102-108. doi: 10.2741/E849.

Alpha-synuclein in salivary gland as biomarker for Parkinson's disease

Campo F, Carletti R, Fusconi M, Pellicano C, Pontieri FE, Di Gioia CR, de Vincentiis M.

Rev Neurosci. 2019 Jul 26;30(5):455-462. doi: 10.1515/revneuro-2018-0064.

Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

Cilento EM, Jin L, Stewart T, Shi M, Sheng L, Zhang J.

J Neurochem. 2019 Nov;151(4):397-416. doi: 10.1111/jnc.14635. Epub 2019 Jan 31.

A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease

Younce JR, Davis AA, Black KJ.

J Parkinsons Dis. 2019;9(1):63-71. doi: 10.3233/JPD-181448.

Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease

Carrera I, Cacabelos R.

Curr Neuropharmacol. 2019;17(3):295-306. doi: 10.2174/1570159X17666181127125704.

Molecular Mechanisms of Curcumin in Neuroinflammatory Disorders: A Mini Review of Current Evidences

Hatami M, Abdolahi M, Soveyd N, Djalali M, Togha M, Honarvar NM.

Endocr Metab Immune Disord Drug Targets. 2019;19(3):247-258. doi: 10.2174/1871530319666181129103056.

Ropinirole Augmentation for Depression: A Randomized Controlled Trial Pilot Study

Gershon AA, Amiaz R, Shem-David H, Grunhaus L.

J Clin Psychopharmacol. 2019 Jan/Feb;39(1):78-81. doi: 10.1097/JCP.0000000000000984.

A Systematic Review of Interventions for Health Anxiety Presentations Across Diverse Chronic Illnesses

Petricone-Westwood D, Jones G, Mutsaers B, Leclair CS, Tomei C, Trudel G, Dinkel A, Lebel S.

Int J Behav Med. 2019 Feb;26(1):3-16. doi: 10.1007/s12529-018-9748-6.

Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases

Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.

CNS Drugs. 2019 Mar;33(3):209-223. doi: 10.1007/s40263-018-0593-6.

Determinants of Dual-Task Training Effect Size in Parkinson Disease: Who Will Benefit Most?

Strouwen C, Molenaar EALM, Münks L, Broeder S, Ginis P, Bloem BR, Nieuwboer A, Heremans E.

J Neurol Phys Ther. 2019 Jan;43(1):3-11. doi: 10.1097/NPT.0000000000000247.

A High-Intensity Exercise Boot Camp for Persons With Parkinson Disease: A Phase II, Pragmatic, Randomized Clinical Trial of Feasibility, Safety, Signal of Efficacy, and Disease Mechanisms

Landers MR, Navalta JW, Murtishaw AS, Kinney JW, Pirio Richardson S.

J Neurol Phys Ther. 2019 Jan;43(1):12-25. doi: 10.1097/NPT.0000000000000249.

Exercise and Parkinson Disease: Comparing Tango, Treadmill, and Stretching

Rawson KS, McNeely ME, Duncan RP, Pickett KA, Perlmutter JS, Earhart GM.

J Neurol Phys Ther. 2019 Jan;43(1):26-32. doi: 10.1097/NPT.0000000000000245.

Predicting Motor Sequence Learning in People With Parkinson Disease

Olivier GN, Paul SS, Lohse KR, Walter CS, Schaefer SY, Dibble LE.

J Neurol Phys Ther. 2019 Jan;43(1):33-41. doi: 10.1097/NPT.0000000000000251.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias